Stevanato Group S.p.A. research snapshot
STVN AI stock analysis reads Stevanato Group as a specialized pharmaceutical glass packaging and drug delivery systems company with a strong position in EZ-fill ready-to-use syringes, cartridges, and pen injector platforms. At the August 3, 2026 cutoff, the latest verified close was $19.85 on July 31, 2026, market capitalization was about $5.42 billion, and the stock has moved back above its 50-day and 200-day moving averages after a multi-month recovery from the $12.89 low. The central question is whether GLP-1 drug demand, the Alina and Deora pen injector platforms, and the Fishers and Latina facility ramp-ups can keep revenue growing near a high-single-digit to low-double-digit pace while free cash flow finally turns positive. This is informational research and not investment advice.
Current price
$19.85
Market cap
$5.42 billion
AI score
65 / 100
Rating
Good business at a fair price with improving momentum and execution risk
Trend status
Above 50-day and 200-day moving averages
Data cutoff (updated monthly)
August 4, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Stevanato makes glass vials, syringes, cartridges, ampoules, pen injectors, and drug delivery systems for pharma and biotech customers who face high switching costs once a containment or delivery solution is qualified for a drug. High-value solutions reached about 47% of revenue in Q1 2026. | High |
| Moat | The moat comes from regulatory switching costs, global manufacturing scale, the proprietary EZ-fill ready-to-use platform, glass forming technology, and long-term relationships with top pharma companies. The Alina and Deora pen injector platforms add a delivery-device layer to the containment franchise. | Medium-high |
| Management | Family-led by CEO Franco Stevanato with three generations of industry knowledge. Capital allocation has shifted from heavy capacity buildout toward harvesting returns: 2025 free cash flow turned positive and the adjusted EBITDA margin reached about 23.9% in Q1 2026. The key question is whether the Fishers and Latina plants deliver the promised margin uplift. | Medium |
| Financial trend | FY2025 revenue of EUR 1,186 million grew 7.45% and net income of EUR 139.8 million grew 18.7%. Q1 2026 revenue rose 6.6% reported and 10.0% at constant currency. Trailing-twelve-month revenue was about $1.39 billion, and free cash flow for FY2025 turned positive at EUR 22.3 million after years of negative FCF. | Medium-high |
| Valuation | The stock traded near 33.8x trailing earnings and 27.4x forward earnings as of the cutoff, with an enterprise value of about $5.81 billion and EV/EBITDA around 24.8x. The PEG ratio was about 1.6. Valuation is lower than its own history but not cheap, so margin of safety depends on growth delivery and FCF improvement. | Medium |
| Technical trend | STVN closed at $19.85 on July 31, 2026, above both its 50-day moving average of $18.56 and its 200-day moving average of $18.76. The stock recovered from the $12.89 52-week low but faces resistance near the $20.40 to $21.00 zone from July swing highs. | Medium |
| Risk level | Key risks are customer concentration, pharma end-market cyclicality and destocking, new plant ramp-up execution in Fishers and Latina, still-modest free cash flow, currency exposure, and competition from West Pharmaceutical, Gerresheimer, and Schott. | Medium-high |
| AI confidence | Medium-high confidence for business model understanding, filing-backed financial data, and major risk categories. Lower confidence for near-term price direction, GLP-1 demand elasticity, and competitive market share evolution. | Medium-high |
| Investment certainty | Medium certainty. The business has durable demand drivers and improving financial momentum, but the current valuation already reflects a recovery, so the reward depends on execution on plant ramp-up and continued GLP-1 and ready-to-use adoption. | Medium |
STVN AI stock forecast
The STVN AI stock forecast uses scenario ranges around the $19.85 cutoff price. It does not claim that AI can predict a specific future price. The bullish case assumes GLP-1 drug demand accelerates, the Alina and Deora pen injector platforms gain customers, the Fishers and Latina plants ramp toward full utilization, and margins and free cash flow keep improving. The base case assumes steady pharma packaging demand with high-single-digit revenue growth. The bearish case assumes plant ramp-up delays, GLP-1 demand disappoints, destocking, or intensifying competition.
$24 to $29
More likely if Stevanato sustains low-double-digit constant-currency revenue growth, adjusted EBITDA margin moves toward the 27-30% target, free cash flow turns sustainably positive, and the market re-rates the stock toward 25-28x forward earnings. The July 2026 authorization of liraglutide combination products using the Alina pen injector platform in Europe supports this case.
$17 to $21
More likely if revenue grows at a high-single-digit pace, the new plants ramp as planned, free cash flow stays modestly positive, and the stock trades in a 23-26x forward PE range near the analyst consensus target of $24.45.
$10 to $14
More likely if Fishers or Latina ramp-up is delayed, GLP-1 drug demand plateaus, pharma customers destock, free cash flow stays near zero or negative, or competitive pressure from West Pharmaceutical, Gerresheimer, or Schott intensifies.
STVN AI technical analysis
STVN AI technical analysis starts from the $19.85 close on July 31, 2026, as of the August 3 data cutoff. The stock sits above its 50-day moving average of $18.56 and 200-day moving average of $18.76. Because this page does not fetch request-time market data, traders should confirm levels on a live chart before acting.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $19.85 | Close on July 31, 2026, used for this page as of the August 3, 2026 data cutoff. |
| Near support | $18.56 to $18.76 | The 50-day and 200-day moving averages form a support zone. A sustained hold above this area keeps the recovery setup intact. |
| Key support | $17.00 to $17.50 | A lower support zone from early July 2026 trading. A break below it would open the way toward the $12.89 52-week low. |
| Near resistance | $20.40 to $21.00 | The July swing high zone. A close above $21.00 would mark a higher high and confirm trend improvement. |
| Key resistance | $24.45 to $28.00 | The $24.45 analyst consensus target and the $28.00 52-week high are the main overhead levels for a durable uptrend. |
| Moving averages | Above 50-day and 200-day | As of the cutoff, STVN closed above its 50-day moving average of $18.56 and 200-day moving average of $18.76, a constructive crossover in the recovery. |
| Momentum | Neutral to positive | The RSI was about 56.8 near the cutoff, leaving room for further upside without being overbought. |
| Volume | Light to moderate | 20-day average volume was about 300,000 shares. The July recovery rally has been on modest volume, so confirmation of a breakout needs volume support. |
| Volatility | Elevated | With a beta of 0.78 and a wide 52-week range from $12.89 to $28.00, position sizing should account for above-normal single-stock volatility. |
| Invalidation | Close below $18.50 or above $21.00 | A daily close below the $18.50 area weakens the recovery setup. A daily close above $21.00 confirms a new uptrend toward the analyst target zone. |
STVN AI trading strategy
The STVN AI trading strategy is a rules-based framework, not personalized advice. It combines filing-backed business evidence, technical confirmation, position sizing, and clear invalidation levels, and it is updated to the August 3, 2026 data cutoff.
Look for STVN to hold above its 50-day and 200-day moving averages and then close above the $20.40 to $21.00 resistance zone on rising volume before treating the recovery as a confirmed uptrend.
A failed breakout, a daily close back below $18.50, or a breach of the July low near $18.74 should reduce confidence in the recovery setup.
If STVN pulls back toward the $18.56 to $18.76 moving-average zone without a broken thesis, monitor Q2 2026 results on August 4, 2026, plant utilization updates, and Alina or Deora customer wins for fundamental confirmation.
Do not average down solely because Stevanato has a strong niche. Define maximum position loss and review free cash flow and capex trends first.
Track quarterly revenue growth at constant currency, high-value solution mix, EZ-fill and GLP-1-related order trends, Fishers and Latina utilization, adjusted EBITDA margin progress toward the 30% target, and free cash flow trajectory.
Lower the rating if revenue growth decelerates below 8% constant currency, if free cash flow slips back negative, or if the adjusted EBITDA margin stalls below 25% without a clear path to the target.
Investment research summary
Stevanato makes specialized glass containers, ready-to-use syringes and cartridges, and drug delivery devices for injectable pharmaceuticals, with customers locked in by regulatory qualification and quality validation processes.
The moat is built on regulatory switching costs, global manufacturing footprint, the proprietary EZ-fill ready-to-use platform, glass forming machinery know-how, new Alina and Deora pen injector platforms, and decades-long customer relationships with top pharma companies.
The thesis can fail if the Fishers and Latina plants underperform on utilization, GLP-1 drug demand plateaus, pharma customers destock again, competition from West Pharmaceutical or Gerresheimer intensifies, or free cash flow fails to stay positive.
The Stevanato family has operated the business since 1949 with strong industry knowledge. Capital allocation has moved from a heavy growth-capex phase to a return-generation phase, with 2025 free cash flow turning positive. Monitoring items include plant ramp-up timelines, FCF conversion, and succession depth.
Stevanato sits at the intersection of injectable drug growth, GLP-1 expansion, biologics demand, and the shift toward ready-to-use containment and delivery solutions. The secular trend is strong, though the industry remains cyclical with pharma end-market spending and destocking risk.
At roughly 33.8x trailing earnings and 27.4x forward earnings with an EV/EBITDA near 24.8x, the stock priced in a recovery but left limited room for execution missteps. A margin of safety requires either durable high-single-digit to low-double-digit growth plus sustained positive free cash flow, or a lower entry price.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| STVN price | $19.85 close on July 31, 2026 | StockAnalysis.com (S&P Global Market Intelligence) | August 2, 2026 |
| Market capitalization | $5.42 billion, verified as $19.85 x 273,000,000 shares | financial_rigor.py market cap verification and StockAnalysis.com | August 2, 2026 |
| TTM revenue | About $1.39 billion (EUR 1,203 million, up 6.99%) | StockAnalysis.com (S&P Global Market Intelligence) | July 31, 2026 |
| FY2025 revenue | EUR 1,186 million, up 7.45% | Company 6-K filing and StockAnalysis.com | May 7, 2026 |
| TTM net income | About $162.98 million (EUR 141.4 million) | StockAnalysis.com (S&P Global Market Intelligence) | August 2, 2026 |
| FY2025 net income | EUR 139.8 million, up 18.73% | Company 6-K filing and StockAnalysis.com | July 31, 2026 |
| EPS (TTM) | $0.59 | StockAnalysis.com (S&P Global Market Intelligence) | August 2, 2026 |
| Cash and equivalents | $129.45 million as of March 31, 2026 | StockAnalysis.com (S&P Global Market Intelligence) | August 2, 2026 |
| Total debt | $519.52 million as of March 31, 2026 | StockAnalysis.com (S&P Global Market Intelligence) | August 2, 2026 |
| Enterprise value | About $5.81 billion | StockAnalysis.com (S&P Global Market Intelligence) | August 2, 2026 |
| TTM PE ratio | 33.76x, verified via financial_rigor.py | financial_rigor.py valuation verification and StockAnalysis.com | August 2, 2026 |
| Forward PE ratio | About 27.35x | StockAnalysis.com (S&P Global Market Intelligence) | August 2, 2026 |
| Dividend yield | 0.31% ($0.06 annual) | StockAnalysis.com (S&P Global Market Intelligence) | August 2, 2026 |
| Analyst consensus | Buy, average target $24.45 from 11 analysts (range $17.50 to $32) | StockAnalysis.com (S&P Global Market Intelligence) | July 21, 2026 |
| 52-week range | $12.89 to $28.00 | StockAnalysis.com (S&P Global Market Intelligence) | August 2, 2026 |
This STVN AI stock analysis is an informational tool for research and education only. It is not investment advice, a recommendation, or a guarantee of future performance. Forecast ranges are scenarios based on available data as of August 3, 2026 and can be wrong.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
